2-甲氧基-5-二-(甲氧基)甲基-吡啶 | 133735-66-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-甲氧基-5-二-(甲氧基)甲基-吡啶
• 英文名称: 2-methoxy-5-bis-(methoxy)methyl-pyridine
• 英文别名: 2-methoxy-5-methoxymethylpyridine；Pyridine, 2-methoxy-5-(methoxymethyl)-；2-methoxy-5-(methoxymethyl)pyridine
• CAS: 133735-66-7
• 化学式: C₈H₁₁NO₂
• mdl: MFCD18802472
• 分子量: 153.181
• InChiKey: RHOUZEYZPPQSLE-UHFFFAOYSA-N

物化性质

• 沸点：
  208.8±25.0 °C(Predicted)
• 密度：
  1.050±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲氧基-5-二-(甲氧基)甲基-吡啶 以45%的产率得到
  参考文献：
  名称：

  JELICH, KLAUS

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(dichloromethyl)pyridine 在 sodium methylate 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 2-甲氧基-5-二-(甲氧基)甲基-吡啶
  参考文献：
  名称：

  Process for the preparation of 2-chloro-5-chloromethylpyridine, and new

  摘要：

  一种制备2-氯-5-氯甲基吡啶的方法，化学式为(I)。包括将化学式(II)中R.sup.1代表烷基的2-烷氧基-5-烷氧甲基吡啶衍生物与氯化剂在稀释剂存在下反应，必要时加入反应助剂，在0°C至200°C的温度范围内进行反应。

  公开号：

  US05116993A1

文献信息

• [EN] 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS DE LA 7-ARYL-1,2,4-TRIAZOLO [4,3-A] PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010130423A1

  公开（公告）日：2010-11-18

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及新型Formula (I)的三唑并[4,3-a]吡啶衍生物，其中所有基团如权利要求中所定义。根据本发明的化合物是代谢型谷氨酸受体亚型2 ("mGluR2")的阳性变构调节剂，适用于治疗或预防与谷氨酸功能障碍有关的神经和精神疾病，以及mGluR2代谢型受体亚型参与的疾病。本发明还涉及包括这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及利用这些化合物预防或治疗与mGluR2有关的神经和精神疾病和疾病的用途。
• Preparation of 2-chloro-5-chloromethylpyridine
  申请人：Bayer Aktiengesellschaft

  公开号：US04958025A1

  公开（公告）日：1990-09-18

  A process for the preparation of 2-chloro-5-chloromethyl-pyridine of the formula ##STR1## which comprises reacting nicotinic acid of the formula ##STR2## with phosphorus pentachloride to produce 3-trichloromethylpyridine of the formula ##STR3## reacting the 3-trichloromethylpyridine in a 2nd step with an alkali metal alkoxide of the formula R-O-M (IV) in which R represents alkyl and M represaents an alkali metal cation, to produce a pyridine ether acetal of the formula ##STR4## reacting the pyridine ether acetal in a 3rd step with dilute aqueous acid to produce pyridone aldehyde of the formula ##STR5## hydrogenating the pyridone aldehyde in a 4th step with molecular hydrogen in the presence of a hydrogenation catalyst to produce the pyridylmethanol compound of the formula ##STR6## and reducing the pyridylmethanol compound in a 5th step with a chlorinating agent.

  一种制备2-氯-5-氯甲基吡啶的方法，包括将尼古酸与五氯化磷反应，产生3-三氯甲基吡啶，然后将3-三氯甲基吡啶与碱金属烷氧化物反应，产生吡啶醚缩醛，再将吡啶醚缩醛与稀释的水酸反应，产生吡啶酮缩醛，接着在氢化催化剂存在下，用分子氢氢化吡啶酮缩醛，产生吡啶甲醇化合物，最后将吡啶甲醇化合物与氯化剂反应，将其还原。
• Thiazole derivatives
  申请人：Nakajima Takao

  公开号：US20070105919A1

  公开（公告）日：2007-05-10

  (Wherein n is an integer of from 0 to 3; R 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R 2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR 8 , or the like; R 3 and R 4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR 12 , or the like) For example, provided are adenosine A 2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.

  其中n为0至3的整数；R1代表取代或未取代的环烷基、取代或未取代的芳基、取代或未取代的脂环杂环基或取代或未取代的芳香杂环基；R2代表卤素、取代或未取代的低碳基、取代或未取代的芳基、取代或未取代的脂环杂环基、取代或未取代的芳香杂环基、-COR8或类似物；R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的低碳基、取代或未取代的芳基烷基、-COR12或类似物。例如，提供了包含噻唑衍生物的腺苷A2A受体拮抗剂作为活性成分，其表示为通式（I）或其药学上可接受的盐等。
• THIAZOLE DERIVATIVES
  申请人：Nakajima Takao

  公开号：US20110105486A1

  公开（公告）日：2011-05-05

  Wherein n is an integer of from 0 to 3; R 1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R 2A is —COR 8 (wherein R 8 is aryl); R 3A is hydrogen or lower alkyl; and R 12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R 1A , R 2A , R 3A and R 12 are individually optionally substituted.

  其中n是0到3的整数；R1A是一个含有至少一个氧原子的5-成员芳香杂环基团；R2A是-COR8（其中R8是芳香基）；R3A是氢或较低的烷基；而R12代表环烷基，芳香基，芳基烷基，脂环杂环基团，芳香杂环基团，脂环杂环烷基或芳香杂环烷基，R1A，R2A，R3A和R12都可以个别地选择性地被取代。
• 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Cic-Nunez Jose Maria

  公开号：US20120184528A1

  公开（公告）日：2012-07-19

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR 2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR 2 is involved.

  本发明涉及式（I）的新型三唑并[4,3-a]吡啶衍生物，其中所有基团如权利要求中所定义。根据本发明的化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，有用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体mGluR2亚型的疾病。本发明还涉及包含这些化合物的制药组合物，制备这些化合物和组合物的过程，以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病。